NEW YORK (Reuters) - After a brutal selloff that sent shares of small companies reeling, some investors have been starting to come back selectively to some of those stocks, but for the group as a whole, recovery could take a while.
The so-called small cap stocks of the Russell 2000 index <.rut> are seen as the canaries in the economic coal mine. When the economy is expanding, these stocks tend to lead the market higher faster. But when recession looms, they tend to do worse first, possibly because more of them live on narrow margins and borrowed money.Right now, they are still signaling gloom ahead. The index is down 27 percent from its June 2015 high and three quarters of the companies in that index have lost at least 20 percent, which puts them officially in bear market territory.But some investors are starting to sift through the wreckage for bargains. Managers of so-called "all-cap funds", who are free to invest in companies of all sizes, have shifted their allocations towards smaller companies to an average of over 20 percent, the highest in the last three years, according to Lipper data. "In the U.S. at least, it is probably the most compelling place to be looking right now," said Bryant Evans, investment advisor and portfolio manager at Cozad Asset Management in Champaign, Illinois. With the crumbling prices, shares have become more affordable. Stocks in the Russell 2000 now are priced at an average of 20 times their expected earnings for the next 12 months, well in line with traditional valuations for smaller companies and cheaper than the 25.8 during the June high. But the risks of prolonged economic weakness and stock market selling have investors fearful of buying the whole group. Instead, it becomes a cherry-picking contest. Investors such as Steve DeNichilo, portfolio manager of the Federated Kaufmann Small Cap Fund in New York, looking carefully at corporate metrics to choose purchases."In this type of market you can’t make a sector prognosis, it is always going to be stock-specific," said DeNichilo, who as of his most recent report was buying molecular diagnostics company Veracyte